Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and Cancer of Prostate

irinotecan has been researched along with Cancer of Prostate in 33 studies

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (6.06)18.2507
2000's15 (45.45)29.6817
2010's16 (48.48)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L1
Doi, H; Inui, T; Kataoka, Y; Kida, T; Nakatsuji, M; Nishino, K; Sakamoto, S; Shimizu, S; Tamura, Y; Teraoka, Y1
Afkham, A; Afkham, NM; Aghebati-Maleki, L; Ahmadi, M; Akbarzadeh, P; Dolati, S; Jadidi-Niaragh, F; Sadreddini, S; Siahmansouri, H; Younesi, V; Yousefi, M1
Abe, T; Fukaya, M; Itatsu, K; Nagino, M; Yokoyama, Y1
Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Karamil, S; Korkmaz, KS1
Aoyama, T; Hamano, T; Hashimura, T; Kawai, J; Kimura, H; Uegaki, M1
McGregor, N; Pienta, KJ; Wang, X; Wu, M; Zhang, J1
Chen, SH; Chern, CS; Chiang, WH; Chiu, HC; Huang, CW; Huang, WC; Lo, CL1
Cuvillier, O; Doumerc, N; Golzio, M; Kohama, T; Malavaud, B; Naymark, M; Pchejetski, D; Teissié, J; Waxman, J1
Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W1
Izumi, K; Mouri, H; Ohtsubo, K; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K; Zen, Y1
Aigner, A; Czubayko, F; Frömberg, A; Gutsch, D; Schulze, D; Vollbracht, C; Weiss, G1
Gleave, M; Gout, PW; Liu, DM; Tung, WL; Wang, Y1
Cui, J; Li, C; Li, Y; Wang, C; Wang, P; Wei, N; Xiu, X; Zhang, L1
Debelec-Butuner, B; Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Korkmaz, KS; Muhammed Syed, H; Ozmen, B; Varisli, L; Yilmazer-Cakmak, O1
Bander, NH; Farokhzad, OC; Gadde, S; Kantoff, PW; Karnik, R; Langer, R; Lippard, SJ; Perea, B; Pridgen, EM; Sweeney, C; Valencia, PM1
Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR1
Commes, T; Hammers, H; Kachhap, SK; Kaelber, NS; Kant, H; Kim, E; Liu, JO; Mendonca, J; Shim, JS; Van Diest, PJ; Wissing, MD1
Agrawal, S; Wang, H; Yu, D; Zhang, R1
Almasan, A; Ray, S1
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL1
Ganapathi, R; Malathi, K; Paranjape, JM; Silverman, RH1
Paukstadt, W1
Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W1
Almasan, A; Fraizer, GC; Ray, S; Shyam, S1
Araki, T; Fujii, M; Inoue, S; Kimoto, K; Murakami, M; Ohshiro, Y; Oka, K; Tacho, T; Yano, A1
Aulicino, C; Benedetti, V; Bucci, F; Carminati, P; De Cesare, M; Foderà, R; Penco, S; Pisano, C; Vesci, L; Zuco, V; Zunino, F1
Guinan, P; Lievano, G; Mirochnik, Y; Rubenstein, M; Shaw, M1
Michael, M; Moore, MJ1
Bigg, D; Carlson, M; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, P; Lauer, J; Lavergne, O1
Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T1
Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D1
Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R1

Reviews

1 review(s) available for irinotecan and Cancer of Prostate

ArticleYear
[Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2014, Volume: 60, Issue:1

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Creutzfeldt-Jakob Syndrome; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Phosphopyruvate Hydratase; Prostate; Prostatic Neoplasms; Transurethral Resection of Prostate; Treatment Outcome

2014

Other Studies

32 other study(ies) available for irinotecan and Cancer of Prostate

ArticleYear
Camptothecins in tumor homing via an RGD sequence mimetic.
    Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats

2012
Solubility-Improved 10-O-Substituted SN-38 Derivatives with Antitumor Activity.
    ChemMedChem, 2017, 10-20, Volume: 12, Issue:20

    Topics: Animals; Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Male; Mice; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Structure-Activity Relationship

2017
Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:3

    Topics: Antineoplastic Agents; Cadherins; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chitosan; Claudin-1; Drug Delivery Systems; Humans; Irinotecan; Male; Nanoparticles; Prostatic Neoplasms; RNA, Small Interfering; Snail Family Transcription Factors

2018
Two-stage operation for synchronous triple primary cancer of the esophagus, stomach, and ampulla of Vater: report of a case.
    Surgery today, 2014, Volume: 44, Issue:5

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Diagnostic Imaging; Digestive System Surgical Procedures; Esophageal Neoplasms; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Plastic Surgery Procedures; Prostatic Neoplasms; Stomach Neoplasms

2014
DNA damage response (DDR) via NKX3.1 expression in prostate cells.
    The Journal of steroid biochemistry and molecular biology, 2014, Volume: 141

    Topics: Acid Anhydride Hydrolases; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin D1; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Etoposide; Histones; Homeodomain Proteins; Humans; Hydrogen Peroxide; Irinotecan; Male; Metribolone; Mutagens; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Testosterone Congeners; Transcription Factors

2014
Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia.
    Molecular pharmacology, 2014, Volume: 85, Issue:6

    Topics: Antineoplastic Agents; Base Sequence; Benzimidazoles; Camptothecin; Cell Hypoxia; Cell Line, Tumor; DNA Damage; DNA Primers; DNA, Neoplasm; E2F1 Transcription Factor; Humans; Irinotecan; Male; Polymerase Chain Reaction; Prostatic Neoplasms; Rad51 Recombinase; Tumor Suppressor Protein p53; Up-Regulation

2014
Tumor Microenvironment-Responsive Nanoparticle Delivery of Chemotherapy for Enhanced Selective Cellular Uptake and Transportation within Tumor.
    Biomacromolecules, 2016, 12-12, Volume: 17, Issue:12

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Drug Delivery Systems; Hyaluronic Acid; Irinotecan; Macrophages; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Polyesters; Polyglycolic Acid; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment

2016
Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:7

    Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cell Line, Tumor; Cell Survival; Ceramides; Drug Therapy, Combination; Green Fluorescent Proteins; Humans; Irinotecan; Lysophospholipids; Male; Mice; Neoplasm Metastasis; para-Aminobenzoates; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Sphingosine; Treatment Outcome; Xenograft Model Antitumor Assays

2008
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.
    The Prostate, 2010, Feb-01, Volume: 70, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids

2010
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
    International journal of clinical oncology, 2009, Volume: 14, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Neoplasm Recurrence, Local; Peptide Fragments; Prostatic Neoplasms; Recombinant Proteins; Spinal Puncture; Treatment Outcome

2009
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dehydroascorbic Acid; Docetaxel; Drug Synergism; Epirubicin; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine

2011
Use of irinotecan for treatment of small cell carcinoma of the prostate.
    The Prostate, 2011, May-15, Volume: 71, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Therapy, Combination; Humans; Irinotecan; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Subrenal Capsule Assay

2011
Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:6

    Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Capsules; Female; Half-Life; Irinotecan; Lipids; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Polyethylene Glycols; Prostatic Neoplasms; Technology, Pharmaceutical

2011
NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines.
    Biochemical and biophysical research communications, 2011, Oct-14, Volume: 414, Issue:1

    Topics: Androgens; Camptothecin; Cell Line, Tumor; DNA Damage; Histones; Homeodomain Proteins; Humans; Irinotecan; Male; Prostatic Neoplasms; S Phase; Transcription Factors

2011
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
    Nanomedicine (London, England), 2013, Volume: 8, Issue:5

    Topics: Antigens, Surface; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Synergism; Glutamate Carboxypeptidase II; Humans; Irinotecan; Male; Nanoparticles; Polymers; Prostate; Prostatic Neoplasms

2013
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
    International journal of molecular sciences, 2012, Sep-28, Volume: 13, Issue:10

    Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Coculture Techniques; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Interferon-beta; Irinotecan; Male; Prodrugs; Prostatic Neoplasms; Rabbits; Stem Cells

2012
Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells.
    Cancer biology & therapy, 2013, Volume: 14, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cetrimonium; Cetrimonium Compounds; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Middle Aged; Prostatic Neoplasms; RNA, Small Interfering; Surface-Active Agents

2013
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    The Prostate, 2003, Feb-15, Volume: 54, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Fluorouracil; Genetic Therapy; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2003
Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Cancer research, 2003, Aug-01, Volume: 63, Issue:15

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Caspase 3; Caspase 7; Caspases; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Membrane Glycoproteins; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2003
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
    British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured

2003
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
    Cancer research, 2004, Dec-15, Volume: 64, Issue:24

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinase Kinases; Oligoribonucleotides; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Necrosis Factor-alpha

2004
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
    MMW Fortschritte der Medizin, 2004, Nov-18, Volume: 146, Issue:47

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A

2004
Expression of drug pathway proteins is independent of tumour type.
    The Journal of pathology, 2006, Volume: 209, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis

2006
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Enzyme Activation; Humans; Irinotecan; Ligands; Male; Mice; Prostatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Receptors, TNF-Related Apoptosis-Inducing Ligand; S Phase; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous; Tumor Suppressor Proteins

2007
[Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Prostate-Specific Antigen; Prostatic Neoplasms

2007
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:9

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured

2008
Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo.
    Methods and findings in experimental and clinical pharmacology, 1996, Volume: 18, Issue:10

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Tumor Cells, Cultured

1996
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Male; Outcome Assessment, Health Care; Palliative Care; Prostatic Neoplasms; Quality of Life; Research Design

1998
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Enzyme Inhibitors; Growth Inhibitors; Humans; Irinotecan; Male; Mice; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000
[Globalization of anti-cancer therapies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms

2002
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
    International journal of oncology, 2002, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome

2002
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
    International journal of oncology, 2002, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome

2002